Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MVA-BN-CV301 |
Synonyms | |
Therapy Description |
MVA-BN-CV301 is a priming cancer vaccine derived from a modified vaccinia Ankara-Bavarian Nordic (MVA-BN) virus encoding CEA and MUC-1, as well as B7-1, ICAM-1, and LFA-3 costimulatory molecules (TRICOM), which potentially induces cytotoxic T-cell response against tumor cells expressing CEA and MUC-1 (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MVA-BN-CV301 | MVA-BN CV301|MVA BN CV301|MVA-BN-CV-301 | MVA-BN-CV301 is a priming cancer vaccine derived from a modified vaccinia Ankara-Bavarian Nordic (MVA-BN) virus encoding CEA and MUC-1, as well as B7-1, ICAM-1, and LFA-3 costimulatory molecules (TRICOM), which potentially induces cytotoxic T-cell response against tumor cells expressing CEA and MUC-1 (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|